Corporate Overview

Partnering Strategy

iCo is actively looking to identify and acquire the rights to products that have a previous clinical history with potential for ophthalmic uses. iCo then employs various drug delivery technologies, re-doses or reformulates these existing products in order to enable ocular administration and gain additional intellectual property coverage for the product. This strategy enables partners to maximize the value of their existing assets with minimal risk of cross use / cross pricing issues.

If you are interested in partnering with iCo Therapeutics, please contact:

John G. Clement, PhD
Chief Technical & Development Officer

Office: 604-602-9414 ×222
Cell:  778-688-0644